Killem 625 Tablet contains a combination of Amoxycillin 500 mg and Clavulanic Acid 125 mg, formulated to combat a broad spectrum of bacterial infections. Amoxycillin is a beta-lactam antibiotic belonging to the penicillin class, which exerts its bactericidal effect by inhibiting bacterial cell wall synthesis. Clavulanic Acid is a beta-lactamase inhibitor that enhances the efficacy of Amoxycillin by preventing the degradation of the antibiotic by beta-lactamase enzymes produced by resistant bacteria. This synergistic combination makes Killem 625 effective against infections caused by susceptible strains of gram-positive and gram-negative bacteria, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and otitis media. The typical dosage and duration of therapy should be determined by a healthcare professional based on the severity and type of infection, renal function, and patient response. Killem 625 is contraindicated in patients with a history of hypersensitivity to penicillins, cephalosporins, or any component of the formulation. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and hypersensitivity reactions like rash or urticaria. Caution is advised in patients with hepatic or renal impairment. Proper adherence to prescribed dosage and completion of the full course of therapy is essential to prevent resistance development.